Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2 Trial of Ixazomib in Combination With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis

Trial Profile

Phase 1/2 Trial of Ixazomib in Combination With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Jul 2018

At a glance

  • Drugs Cyclophosphamide (Primary) ; Dexamethasone (Primary) ; Ixazomib (Primary)
  • Indications Amyloid light-chain amyloidosis; Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 06 Jul 2018 Planned End Date changed from 22 Oct 2018 to 22 Oct 2020.
    • 06 Jul 2018 Planned primary completion date changed from 22 Oct 2018 to 22 Oct 2020.
    • 30 Jun 2017 Planned End Date changed from 1 Oct 2018 to 22 Oct 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top